Guided Therapeutics Inc
OTC:GTHP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (16.1), the stock would be worth $-0.2 (200% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -16.1 | $0.2 |
0%
|
| Industry Average | 16.1 | $-0.2 |
-200%
|
| Country Average | 13.3 | $-0.17 |
-183%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Guided Therapeutics Inc
OTC:GTHP
|
19.3m USD | -16.1 | -5.1 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
167.2B USD | 55.2 | 58.6 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
161.2B USD | 16.8 | 25.7 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.8B USD | 24.9 | 38.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.4B USD | 14.6 | 23.1 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
88.9B USD | 19.6 | 24.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 30.4 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40.1B EUR | 13.2 | 18.9 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.8B USD | 38.8 | 43.3 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.8B USD | 12.6 | 24.3 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32.3B USD | 16.9 | 21.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.8 |
| Median | 13.3 |
| 70th Percentile | 20.1 |
| Max | 3 188 432.5 |
Other Multiples
Guided Therapeutics Inc
Glance View
Guided Therapeutics, Inc. engages in the development of medical devices. The company is headquartered in Norcross, Georgia. The firm is focused on selling and marketing of its LuViva advanced cervical scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. The firm focuses on two primary applications for LuViva as a cancer screening tool, and triage traditional screening. Screening is for cervical cancer represents the practice of diagnostic medicine. The firm is also focused on the extension of its cancer detection technology into other cancers, including esophageal.
